PRIOR AUTHORIZATION REQUEST FORM EOC ID: Medicare Part D Sprycel

Phone: 800-728-7947 Fax back to: 866-880-4532

Scott & White Prescription Services manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

		Prescriber Name:	
Patient Name:		Supervising Physician:	
Member/Subscriber Number:		Fax:	Phone:
Date of Birth:		Office Contact:	
Group Number:		NPI:	State Lic ID:
Address:		Address:	
City, State ZIP:		City, State ZIP:	
Primary Phone:		Specialty/facility name (if applic	cable):
Drug Name and Strength:			
Directions / SIG:			
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.			
Q1. Is this patient a new start? *			
☐ Yes ☐ No	0		
Q2. What diagnosis is this drug being prescribed for?			
☐ Philadelphia chromosome positi	ve Acute Lymphoid L	eukemia (ALL)	
☐ Philadelphia chromosome positi☐ Other	ve Chronic Myeloid L	eukemia (CML)	
Q3. Please provide ICD code(s) for	diagnosis		
O4 If ALL was the nationt registant	or intolorant of prior t	thorony?	
Q4. If ALL, was the patient resistant		ιι ισι αμγ :	
☐ Yes ☐ No			
Q5. If CML, indicate the phase the o	lisease is in?		
☐ Chronic phase ☐ Ac	ccelerated phase	☐ Myeloid blast phase	☐ Lymphoid blast phase
Q6. If chronic phase CML, is the part	tient newly diagnosed	?	

PRIOR AUTHORIZATION REQUEST FORM EOC ID: Medicare Part D Sprycel

Phone: 800-728-7947 Fax back to: 866-880-4532

Scott & White Prescription Services manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process. **Prescriber Name: Patient Name:** Supervising Physician: Yes ☐ No Q7. If chronic, accelerated, myeloid or lymphoid blast phase CML and not newly diagnosed, is the patient resistant or intolerant to prior therapy including imatinib? Yes ☐ No Q8. Is the prescribing physician an Oncologist? ☐ Yes ☐ No Q9. Additional Comments

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Date

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Prescriber Signature